Half-year Report

AI SummaryClose X

Incanthera plc reported its interim results for the six months ended 30 September 2025, highlighting the global launch of its Skin+CELL skincare range via a dedicated Direct To Consumer website, which has shown steady month-on-month increases in traction and sales conversion. The company incurred an operating loss of £888,000 for the period, compared to £695,000 in the prior year, with basic and diluted loss per share at (0.69) pence. Cash and cash equivalents stood at £215,000 as of 30 September 2025, a decrease from £1,058,000 in the previous year, reflecting net cash used in operating activities of £313,000. The company continues to explore additional routes to market and has seen positive initial traction and consumer feedback for its B3 Face product, its most successful item.

Disclaimer*

UK 100

Latest directors dealings